Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: A biomarker evaluation from the AVAGAST randomized phase III trial
Antibodies, Monoclonal, Humanized
Antineoplastic Combined Chemotherapy Protocols
Plasma VEGF-A and tumor neuropilin-1 are strong biomarker candidates for predicting clinical outcome in patients with advanced gastric cancer treated with bevacizumab.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency